logo

Advaxis Inc. (ADXS)



Trade ADXS now with
  Date
  Headline
7/13/2018 8:04:04 AM Advaxis Announces FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac With Durvalumab
6/7/2018 9:06:47 AM Advaxis Q2 Net Loss $13.4 Mln Or $0.27/Shr Vs Loss $20.5 Mln Or $0.51/Shr Last Year
6/6/2018 8:04:13 AM Advaxis Appoints Molly Henderson As EVP And CFO
4/23/2018 8:20:46 AM Advaxis Appoints Kenneth Berlin As President And CEO
3/12/2018 4:10:32 PM Advaxis Trading Expected To Resume At 4:35 PM ET
3/12/2018 4:01:49 PM Advaxis Trading Halted ; Pending News
2/22/2018 9:22:43 AM Advaxis Prices $20 Mln Public Offering Of Common Stock
2/13/2018 8:42:31 AM Advaxis Submits Conditional MAA For Axalimogene Filolisbac For Second-Line Treatment Of Metastatic Cervical Cancer In EU
2/12/2018 9:18:33 AM Advaxis Publishes Phase2 Results Evaluating Axalimogene Filolisbac For Treatment Of Recurrent Metastatic Cervical Cancer